Black Diamond Therapeutics Statistics
Share Statistics
Black Diamond Therapeutics has 56.59M shares outstanding. The number of shares has increased by 9.43% in one year.
| Shares Outstanding | 56.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.45% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 42.93M |
| Failed to Deliver (FTD) Shares | 2.13K |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 6.33M, so 11.18% of the outstanding shares have been sold short.
| Short Interest | 6.33M |
| Short % of Shares Out | 11.18% |
| Short % of Float | 14.75% |
| Short Ratio (days to cover) | 7.7 |
Valuation Ratios
The PE ratio is -1.5 and the forward PE ratio is -2.66.
| PE Ratio | -1.5 |
| Forward PE | -2.66 |
| PS Ratio | 0 |
| Forward PS | 327.5 |
| PB Ratio | 1.06 |
| P/FCF Ratio | -1.85 |
| PEG Ratio | n/a |
Enterprise Valuation
Black Diamond Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.82, with a Debt / Equity ratio of 0.
| Current Ratio | 6.82 |
| Quick Ratio | 6.82 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on capital (ROIC) is -60.87%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -0.52% |
| Return on Capital (ROIC) | -60.87% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.53M |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -6.27% in the last 52 weeks. The beta is 2.52, so Black Diamond Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.52 |
| 52-Week Price Change | -6.27% |
| 50-Day Moving Average | 2.93 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (20 Days) | 1.19M |
Income Statement
In the last 12 months, Black Diamond Therapeutics had revenue of $0 and earned -$82.44M in profits. Earnings per share was $-1.88.
| Revenue | 0 |
| Gross Profit | -437.00K |
| Operating Income | -86.46M |
| Net Income | -82.44M |
| EBITDA | -86.02M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has $56.22M in cash and $25.30M in debt, giving a net cash position of $30.92M.
| Cash & Cash Equivalents | 56.22M |
| Total Debt | 25.30M |
| Net Cash | 30.92M |
| Retained Earnings | -417.43M |
| Total Assets | 137.90M |
| Working Capital | 94.74M |
Cash Flow
In the last 12 months, operating cash flow was -$66.72M and capital expenditures -$33.00K, giving a free cash flow of -$66.75M.
| Operating Cash Flow | -66.72M |
| Capital Expenditures | -33.00K |
| Free Cash Flow | -66.75M |
| FCF Per Share | -1.52 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -74.02% |
| FCF Yield | -46.53% |
Analyst Forecast
The average price target for BDTX is $15.5, which is 510.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 510.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.77 |
| Piotroski F-Score | 2 |